Tenofovir and bone health : Current Opinion in HIV and AIDS Tenofovir and bone health :
Current Opinion in HIV and AIDS Log in or Register Subscribe to journalSubscribe Get new …

It has been demonstrated that patients on highly active antiretroviral therapy are at
increased risk for developing metabolic abnormalities that include elevated levels of serum …

Objectives: To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir
alafenamide (TAF), as part of the first protease inhibitor–based single-tablet regimen (STR) …

Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1
(HIV) infection has led to marked improvement in life-expectancy for those infected with HIV …

Several reports have suggested an increased prevalence of osteopenia and osteoporosis in
HIV-infected individuals. Vitamin D deficiency may be a risk factor for osteoporosis and bone …

Objective: To evaluate a simplification strategy for HIV-1-infected patients virologically
suppressed on antiretroviral therapy (ART) by switching to a single-tablet regimen consisting …

Background Antiretroviral drugs have been associated with changes in lipids, fat mass and
dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more …

Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has been an important
component of the treatment of HIV infection for 10 years and has contributed significantly to …

In the antiretroviral therapy (ART) era, serious non-AIDS events (SNAEs) have become the
major causes of morbidity and mortality in HIV-infected persons. Early ART initiation has the …

Several studies have reported improvement in lipids after antiretroviral therapy switches to
tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects …